Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Ozempic: DH recommends alternative diabetes drugs as shortages persist

The DH has said that patients with type two diabetes can be initiated on or switched to alternative treatments amid ongoing shortages of semaglutide and other GLP-1 RAs.

Patients with type two diabetes can be initiated on Mounjaro Kwikpens (tirzepatide) or Rybelsus tablets (semaglutide), according to a Department of Health and Social Care (DH) medicine supply notification announced by Community Pharmacy England (CPE) this week (March 18).

According to CPE, many glucagon-like peptide-1 receptor agonist (GLP-1 RA) medicines for type two diabetes management will remain in short supply throughout 2024.

CPE said that new patients should not be started on Ozempic injections (semaglutide), Trulicity (dulaglutide) or Bydureon BCise (exenatide).

It added:

  • There will be “intermittent supply” of the 0.25mg, 0.5mg, and 1mg Ozempic solutions – with the 0.5mg dose out of stock until early June - and the 0.75mg, 1.5mg, 3mg and 4.5mg Trulicity solutions throughout 2024
  • Victoza (liraglutide) 6mg/ml solution for injection in a pre-filled pen is out of stock until the end of 2024
  • Byetta (exenatide) 5micrograms/0.02ml and 10micrograms/0.04ml pre-filled pens will be discontinued at the end of this month

However, it said that in the coming months, “higher strengths of tirzepatide” in the form of Mounjaro Kwikpens (7.5mg/0.6ml, 10mg/0.6ml, 12.5mg/0.6ml and 15mg/0.6ml solutions) will be available for patients.

Read more: Diabetes injection pen shortage to persist until ‘at least’ end of 2024

The 2.5mg/0.6ml and 5mg/0.6ml solutions of Mounjaro Kwikpens and Rybelsus (semaglutide) 3mg, 7mg and 14mg tablets are also “now available” and “can support” new initiations and switches, it added.

And Bydureon BCise exenatide 2mg/0.85ml prolonged-release pre-filled pens are available for patients “stabilised on therapy” only, according to CPE.

 

New guidance

 

New guidance from the Primary Care Diabetes Society (PCDS) and Association of British Clinical Diabetologists (ABCD) updated this month also highlighted that other GLP-1 RA products are available to adults with type two diabetes that cannot obtain their “original” medication.

PCDS and ABCD this week (March 18) published the updated guidance to help clinicians choose “alternative glucose-lowering therapies” during the “ongoing national shortage”. 

Read more: What’s the deal with Wegovy?

According to the document, prescribers should “consider prescribing Rybelsus tablets or Mounjaro Kwikpens” to patients prescribed Victoza or Byetta or who have been “unable to obtain Ozempic or Trulicity for two weeks or more”.

And it said that they should not prescribe more than one month’s supply “unless there is clear reason to do so” to ensure the “risks to the supply chain are minimised” or prescribe GLP-1 RAs for anything other than their licensed indication.

Read more: Patients hospitalised by fake Saxenda and Ozempic pens filled with insulin

“Local supply chain issues may be overcome by attending an alternative pharmacy [and] this should be considered before switching therapies,” it added.

In January, the DH announced that GLP-1 RA supply issues would continue “until at least the end of 2024”.

At the time, it said that “clinicians and prescribers” should “identify patients prescribed Byetta and Victoza injections” and switch them to Rybelsus tablets by March 28 and that these tablets should also be prescribed for all new initiations.

Related Content

Topics

         
Pharmacy Manager
Guernsey
£70,000

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD138043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel